Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ibogaine, Monohydrochloride
2. Ibogaine Hcl
3. Ibogaine (hcl)
4. Dl-ibogamine Hydrochloride
5. 5934-55-4
6. Ibogamine, 12-methoxy-, Monohydrochloride
7. Mri8gkd98x
8. Nsc-29847
9. 12-methoxyibogamine Monohydrochloride
10. (1r,15r,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene;hydrochloride
11. 36415-61-9
12. Ibogaine Hydrochloride (van)
13. Einecs 227-687-1
14. Unii-mri8gkd98x
15. Nsc 29847
16. (2r,4s,4as,12br)-4-ethyl-2,5-methano-9-methoxy-2,3,4,4a,6,7,12,12b-octahydro-1h-indolo[3,2-d][1]benzazepine Monohydrochloride
17. Ncgc00247731-01
18. Ibogamine, Monohydrochloride
19. Bogaine Hydrochloride
20. Dsstox_cid_28803
21. Dsstox_rid_83072
22. Dsstox_gsid_48877
23. Ibogaine, Hydrochloride
24. Schembl431979
25. Chembl2360520
26. Dtxsid7048877
27. Ibogaine Monohydrochloride
28. Ibogaine Hydrochloride [mi]
29. Nsc29847
30. Tox21_112897
31. Ibogaine Hydrochloride [vandf]
32. Ibogaine Hydrochloride [who-dd]
33. Cas-36415-61-9
34. Ibogamine, 12-methoxy-, Hydrochloride (1:1)
35. Q27284192
36. Wln: T E6 C5 B766/ns A 2bo S Dm Nn&&tttj Ho1 P2 &gh
Molecular Weight | 346.9 g/mol |
---|---|
Molecular Formula | C20H27ClN2O |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 346.1811912 g/mol |
Monoisotopic Mass | 346.1811912 g/mol |
Topological Polar Surface Area | 28.3 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 455 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10405
Submission : 1992-08-06
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10405
Submission : 1992-08-06
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Details:
3,4-methylenedioxymethamphetamine acts as a releaser of 5-HT and noradrenaline, and to a lesser extent also of dopamine. It is a potent empathogen-entactogen with stimulant properties primarily used for recreational purposes.
Lead Product(s): Midomafetamine,Ibogaine Hydrochloride,Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2023
Lead Product(s) : Midomafetamine,Ibogaine Hydrochloride,Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 3,4-methylenedioxymethamphetamine acts as a releaser of 5-HT and noradrenaline, and to a lesser extent also of dopamine. It is a potent empathogen-entactogen with stimulant properties primarily used for recreational purposes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 22, 2023
Details:
A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial of ibogaine HCl (DMX-1002) in the treatment of opioid use disorder (OUD).
Lead Product(s): Ibogaine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: DMX-1002
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2021
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial of ibogaine HCl (DMX-1002) in the treatment of opioid use disorder (OUD...
Product Name : DMX-1002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2021
Details:
The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).
Lead Product(s): Ibogaine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: DMX-1002
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 24, 2020
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Financing
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
Details : The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).
Product Name : DMX-1002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2020
Market Place
ABOUT THIS PAGE
27
PharmaCompass offers a list of Ibogaine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ibogaine Hydrochloride manufacturer or Ibogaine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ibogaine Hydrochloride manufacturer or Ibogaine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ibogaine Hydrochloride API Price utilized in the formulation of products. Ibogaine Hydrochloride API Price is not always fixed or binding as the Ibogaine Hydrochloride Price is obtained through a variety of data sources. The Ibogaine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ibogaine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibogaine Hydrochloride, including repackagers and relabelers. The FDA regulates Ibogaine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibogaine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ibogaine Hydrochloride supplier is an individual or a company that provides Ibogaine Hydrochloride active pharmaceutical ingredient (API) or Ibogaine Hydrochloride finished formulations upon request. The Ibogaine Hydrochloride suppliers may include Ibogaine Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Ibogaine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ibogaine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Ibogaine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Ibogaine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Ibogaine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ibogaine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Ibogaine Hydrochloride USDMF includes data on Ibogaine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ibogaine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ibogaine Hydrochloride suppliers with USDMF on PharmaCompass.
Ibogaine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ibogaine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ibogaine Hydrochloride GMP manufacturer or Ibogaine Hydrochloride GMP API supplier for your needs.
A Ibogaine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Ibogaine Hydrochloride's compliance with Ibogaine Hydrochloride specifications and serves as a tool for batch-level quality control.
Ibogaine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Ibogaine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ibogaine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Ibogaine Hydrochloride EP), Ibogaine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ibogaine Hydrochloride USP).